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Sepsis is a complex clinical syndrome that features excessive release of cytokines and other inflammatory mediators that could
lead to organ dysfunction. Despite different treatment and management options, sepsis associated high morbidity and mortality
rates remain. This has prompted intensive research into alternative therapeutic approaches such as targeted removal of sepsis
related molecules using extracorporeal hemoperfusion. In this study, we explore the use of graphene nanoplatelets (GNP) as low-
cost alternative hemosorbents for rapid removal of a broad spectrum of proinflammatory cytokine markers. Firstly, the physical
characteristics, cytotoxicity, and cytokine marker adsorption profile of GNP were assessed. The results not only confirmed the
surface characteristics of GNP and their ability to rapidly remove cytokine markers, but also indicated a low cytotoxicity towards
the hepatic cell line HepG2. GNP were then incorporated into a freestanding flexible GNP-poly(tetrafluoroethylene) film with
preserved surface characteristics and cytokine adsorption profile for potential use in hemoperfusion applications.
1. Introduction
Sepsis is a life-threatening condition caused by the body’s
disregulated host response to infection. Between 1993 and
2003, the number of hospitalizations for severe sepsis doubled
in the United States [1]. Sepsis is the primary cause of death
for children and infants [2, 3], and the number of incidences
was estimated at over 19million casesworldwide annually [4].
Sepsis conditions progress as a function of the cytokine cas-
cade, an exaggerated immune response to the incident infec-
tion [5]. Although the exact mechanism of sepsis remains
poorly understood, it is believed that high concentrations of
proinflammatory cytokines, such as IL-6, IL-8, and TNF-𝛼
contribute to the progression of sepsis in patients [6, 7].
Current sepsis treatment methods consist of treating the
underlying infection using broad spectrum antibiotics and
remediating hemodynamic changes through fluid resuscita-
tion [8]. Recently, the use of extracorporeal blood purification
has been investigated as an alternative approach to sepsis
treatment through the removal of substances linked to the
pathogenesis of sepsis. Endotoxins have been identified as
key substances in sepsis progression, and polymyxin B-
immobilized columns have been designed for the removal
of endotoxins through direct hemoperfusion [9]. Despite
the successful targeted removal of endotoxins from septic
patients, clinical trials have shown an inconclusive benefit
in the removal of endotoxins alone [10, 11]. The removal
of inflammatory cytokines has also attracted increasing
Hindawi
Journal of Nanomaterials
Volume 2018, Article ID 6274072, 8 pages
https://doi.org/10.1155/2018/6274072
2 Journal of Nanomaterials
Graphene
nanoplatelet
+
polytetrauoroethylene in 
ethanol 
(a) (b) (c)
Freestanding, exible graphene 
nanoplatelet-
polytetrauoroethylene lm
(d)(e)
1
–5
Ｈ
Ｇ
 
IL-6
IL-8
Ｇ
TNF
Submicron, 100
Figure 1: Schematic diagrams showing (a) the layered, open structure of graphene nanoplatelets (GNP)which are suitable for broad spectrum
proinflammatory cytokine removal and (b) the use of PTFE, as a binder to produce the (c) freestanding flexible GNP-PTFE film with (d)
exposed GNP surfaces and PTFE holding the GNP (indicated by yellow arrow), indicating a potential route for use in (e) hemoperfusion.
attention as an option for sepsis treatment. Polymeric porous
adsorbents such as CytoSorb (CytoSorbents Corporation,
USA) have been developed for target removal of molecules
between 10 and 50 kDa and have shown some success in both
animal studies and clinical case studies [12, 13]. Furthermore,
synthetic activated carbon (AC) is also an attractive adsor-
bent for hemoperfusion systems, as its inert character and
tunable porosity (e.g., mesomacroporous texture) allow for
optimal adsorption of proteins with different dimensions.
Recent work has utilized carbon in the form of AC [14],
carbide-derived carbons [15, 16], and polymer-pyrolyzed
carbon monoliths [17] for use in adsorbing overexpressed
cytokines and other toxins inherent in septic patients. These
amorphous and graphitic carbons rely on an internally
accessible surface area and entrapment of proteins by slit-
shaped pores for adsorption [18].
While the results of these previous investigations have
shown a viable proof-of-concept and efficient adsorption of
these cytokines, these adsorbents lack rapid kinetics due to a
complex adsorption model [14, 19]. More advanced synthetic
materials have a high manufacturing cost. Graphene
nanoplatelets (GNP) are a new, commercially available, low-
cost graphene material that consists of stacks of graphene
layers 1–5 nm in thickness and tunable lateral dimensions
ranging from submicron scale to over 100 𝜇m, as determined
by milling and processing [20]. GNP have an openly
accessible and large specific surface area (∼500m2/g) [21],
making them an ideal material for rapid protein adsorption
(Figure 1(a)). Typical GNP synthesis involves mechanical
exfoliation of expanded graphite prepared from natural
graphite [22, 23]. Previous report has tested the suitability of
expanded graphite materials with inert surface and abundant
macropores for large molecule adsorption and bacteriostatic
properties and, subsequently, demonstrated potential for
medical applications as wound dressings [24]. Owing to the
abundant supply and low price of the source natural graphite
material, GNP warrants further investigation as a potential
cost-effectivemedical adsorbent. In this paper, we explore the
use of noncytotoxic graphene nanoplatelets for rapid removal
of a broad spectrum of proinflammatory cytokines identified
as instigators of sepsis progression and the preparation of
a freestanding flexible GNP-poly(tetrafluoroethylene) film
(Figures 1(b) and 1(c)) with preserved surface (Figure 1(d))
and cytokine adsorption characteristics for practical use in
hemoperfusion applications (Figure 1(e)).
2. Materials and Methods
2.1.Material Synthesis. TheGNPused in this studywasGrade
C-500 xGnPTM obtained from XG Sciences© (Lansing, MI,
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USA). GNP was vacuum annealed (10−6 torr) at 1800∘C for
eight hours in a vacuum furnace (Solar Atmospheres, PA,
USA) to remove functional groups, graphitize the surface of
the GNP, and produce vacuum annealed GNP (VA-GNP).
VA-GNP-PTFE film was prepared by mixing defunction-
alized VA-GNP with PTFE (60% w/w in water) solution
(Sigma-Aldrich, US) in ethanol at a ratio of 19 : 1. Evaporation
of ethanol left a homogenous VA-GNP-PTFE dense slurry
which was rolled out into a cohesive, freestanding 100 𝜇m
thick film. The resulting film was then subjected to nitrogen
adsorption analysis and cytokine removal assessments to
establish its efficacy as a hemoadsorbent.
2.2. Material Characterization. GNP particle size was deter-
mined by dynamic light scattering (DLS) using Zetasizer
Nano ZS (Malvern, UK). High magnification images of
GNP were obtained using transmission electron microscopy
(TEM) (JEM2100, JEOL, Japan). The surface and internal
porous morphologies of GNP powder and GNP-PTFE film
were characterized by scanning electron microscopy (SEM)
(Zeiss Supra 50VP field-emission SEM, USA). Quadrasorb
pore size analyzer (Quantachrome, FL, USA) was used
to measure specific surface area and porosity by carrying
out N
2
adsorption-desorption measurements at 0.05–0.99
𝑃/𝑃
0
relative pressures at 77.4 K. The data was analyzed
using Quantachrome data analysis software (Quantachrome
QuadraWin 5.1). The specific surface areas were calculated
using the Brunauer, Emmett, and Teller (BET) method while
the pore size distribution was estimated using quenched solid
density functional theory (QSDFT) modelling.
2.3. Biocompatibility Assessment. To ensure the safety of
GNP, its cytotoxicity was also assessed. The liver, as the main
organ for detoxification, has been reported to accumulate
nanoparticles after their injection in the bloodstream [25, 26].
A human hepatic epithelial cell line HepG2 (CRL-11997,
ATCC, VA, USA) was used for the assessment of GNP
cytotoxicity, with silver nanoparticles as a positive control due
to their widely reported cytotoxicity and hepatocytotoxicity
[27, 28]. HepG2 cell viability after treatments was determined
by comparing cellular 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) conversion using CellTiter 96AqueousOne Solution
Cell Proliferation Assay (Promega, Southampton, UK), while
the material cytotoxicity was assessed through the level of
lactate dehydrogenase (LDH) released by the HepG2 cells
using CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Southampton, UK).
2.4. Cytokine Adsorption Experiments. The cytokine marker
adsorption profile of GNP was first evaluated by incubating
10% v/v of GNP with fresh frozen human blood plasma
(Cambridge Bioscience Ltd., Cambridge, UK) spiked with
1 ng/mL IL-8, IL-1𝛽, IL-6, IL-10, and TNF-𝛼 (BD Biosciences,
UK) for 60 minutes. Concentrations of the selected cytokine
marker were determined using BD Cytometric Bead Array
(CBA) Human Inflammatory Cytokines Kit (BD Biosciences,
UK). The GNP-PTFE film adsorption kinetics of selected
cytokine markers IL-8, IL-6, and TNF-𝛼 was compared
with PTFE film and GNP powder. The selected cytokine
marker concentrations were measured by enzyme-linked
immunosorbent assay (ELISA) using BD Biosciences ELISA
set. Two-way ANOVA statistical analysis was performed
using Prism 6 version 6.05 (GraphPad Software, Inc.).
3. Results and Discussion
3.1. Material Morphology and Surface Characteristics. In the
untreated GNP samples, loose agglomerates of GNP can
be observed under SEM (Figure 2(a)). At a higher mag-
nification, SEM images revealed that these agglomerates
consisted of submicron size particles (Figure 2(b)). After
sonication in ethanol, smaller agglomerates of GNP and
single nanoplatelets were observed under TEM (Figure 2(c)),
revealing their multilayer-stacked graphene structure. Under
higher magnification, a single nanoplatelet can be observed
from a top-down perspective in TEM (Figure 2(c)). VA-GNP
showed a 2.7-fold decrease in specific surface area and pore
volume as compared to GNP. This was observed along with
a 3-fold increase in VA-GNP particle size as compared to
GNP determined by dynamic light scattering (DLS) analysis.
The decrease in surface area is caused by the restacking of
graphene planes during annealing [29]. However, increased
agglomeration of defunctionalized hydrophobic VA-GNP in
water is mainly responsible for the DLS-observed increase
in their particle sizes. SEM and TEM images revealed the
small particle size and tightly stacked layered structure of
the GNPwith high electron density between graphene layers,
preventing access of N
2
molecules to internal voids in the
material. The large BET surface area of the GNP is attributed
predominantly to its outer accessible surface area. When VA-
GNP was bound by PTFE (VA-GNP-PTFE) (Figure 2(d)),
the film showed a slight decrease in the adsorbed nitrogen
volume (Figure 3(a)) and micropore (<2 nm diameter pores)
volume (Figure 3(b)), while the shape of the isotherm and
the overall pore size distribution remained similar to the
VA-GNP. The specific surface area and micropore volume of
the VA-GNP-PTFE film remained as high as 210m2/g and
0.30 cm3/g, respectively, and only slightly lower than the VA-
GNP alone at 294m2/g and 0.39 cm3/g, respectively (Table 1).
This decrease in the specific surface area and micropore
volume measured by the nitrogen adsorption analysis could
be attributed to the addition of nonporous PTFEpolymer that
reduced the accessible VA-GNP surface to N
2
molecules.
3.2. Cytokine Markers Removal Profile of GNP. Following
materials characterization, cytokine adsorption efficacy of
the GNP-PTFE film was subsequently assessed. The cytokine
marker adsorption profile of GNP showed rapid and efficient
removal of cytokines from human plasma spiked with a
cytokine cocktail. The concentration of smaller cytokines
IL-8 (8 kDa) and IL-1𝛽 (17 kDa) in the spiked plasma was
reduced from over 1500 pg/mL to 20 pg/mL within 5 min-
utes of direct contact (Figure 4(a)). In comparison, GNP
removal of larger cytokine markers IL-10 (18.5 kDa) and IL-6
(20.5 kDa) by GNP appeared to be slightly slower. However,
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Figure 2: (a) SEM image of a GNP agglomerate; (b) higher magnification SEM image revealing submicron GNP particles; (c) TEM image of
a single GNP, indicating a single GNP particle consists of stacks of graphene layers; and (d) SEM image of the GNP-PTFE film in which GNP
particles were held together by PTFE (indicated by arrows).
Table 1: Porosity of GNP, VA-GNP, and VA-GNP-PTFE film determined using low temperature nitrogen adsorption analysis. Sample specific
surface area (𝑆BET) and pore volume (𝑉QSDFT)/size (𝐷mode) were calculated using BET and QSDFT, respectively. Equivalent particle diameter
(𝑑) was determined using dynamic light scattering.
Sample 𝑆BET (m
2/g) 𝑉QSDFT (cm
3/g) 𝐷mode (nm) 𝑑 (nm)
Initial GNP 797 0.807 0.785 547
VA-GNP 294 0.397 0.723 1670
VA-GNP-PTFE 210 0.301 0.852 --
even in these cases 60% and 50% removal, respectively,
were achieved within the first 5min of contact. The TNF-𝛼
trimer (51 kDa) is, reportedly, the most challenging molecule
to remove in conventional blood purification techniques
using carbon sorbents [30–32]. However, a reduction in the
plasma TNF-𝛼 concentration from 868 pg/mL to 55 pg/mL
after 5min contact with GNP indicated a rapid and efficient
removal of the TNF-𝛼 by GNP. The fast adsorption kinetics
can be attributed to direct contact with a completely acces-
sible surface area and minimal diffusion barriers to and on
the surface. These results demonstrated GNP’s potential for
broad spectrum cytokine removal.
3.3. Biocompatibility of GNP. The LDH and MTT cytotoxic-
ity assay results indicated that at lower tested concentrations
GNP caused no or minimal cytotoxic effect (<20% cytotoxi-
city and >80% cell viability) towards HepG2 cells, while the
silver nanoparticles were cytotoxic at concentrations as low
as 0.01% (v/v) (Figures 4(b) and 4(c)). HepG2 cell viability
fell below 60% after 0.06% GNP treatment, indicating a
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Figure 3: (a) Low temperature nitrogen adsorption isotherms (closed circles denote the adsorption branch and open circles denote the
desorption branch) and (b) pore size distributions of the GNP, VA-GNP, and VA-GNP-PTFE film.
suppression of metabolic activity (Figure 4(b)). The cyto-
toxicity of GNP determined using LDH assay appeared
to be dose-dependent and was significantly (𝑝 < 0.01)
lower than the silver nanoparticles at the same concentration
(Figure 4(c)). The slight cytotoxic effects of GNP at the
concentrations of 0.03% and 0.06% are likely attributed to
the large absolute volume of GNP in the two-dimensional
culture system, which blocked cellular access to vital oxygen
and nutrients.
3.4. Cytokine Markers Removal Efficiency of GNP-PTFE Film.
The adsorption data for cytokine markers IL-8 and IL-6 and
TNF-𝛼 revealed that the PTFE film alone did not reduce the
cytokine concentration in the spiked plasma compared to the
control within the 90min incubation cycle. In contrast, when
the spiked plasma was incubated with the GNP particles, IL-
8 concentration reduced from 633 pg/mL to 7 pg/mL within
5min. IL-6 decreased from 477 pg/mL to 22 pg/mL after
5min and further dropped to 8 pg/mL after 30min (Figures
5(a) and 5(b)). The VA-GNP-PTFE film showed a slower
and slightly less efficient adsorption of IL-8 from the spiked
plasma as compared to theGNP, butwith 95% removal of IL-8
over 90min of incubation (Figure 5(a)). A significantly lower
adsorption efficacy of IL-6was observedwithVA-GNP-PTFE
film as compared to the GNP particles, but VA-GNP-PTFE
film removed over 50% of IL-6 from the spiked plasma over
the 90min incubation period (Figure 5(b)). Incorporation of
GNP into the PTFE film reduced TNF-𝛼 removal compared
to the GNP particles alone (Figure 5(c)). This could be due
to the packing of GNP particles, which reduced the exposed
particle outer surface area. Alternatively, PTFE limited acces-
sibility between the particles and potentially contributed to
this effect. We have previously highlighted the need for pores
with diameters that exceed protein molecule size [33]. From
a practical perspective, this translated to meso-/macropores
in activated carbon adsorbents with predominant 70–120 nm
diameter pores as necessary for significant TNF-𝛼 adsorption
[17, 34, 35]. AlthoughGNPwith a similar specific surface area
did not feature such large pores, it still demonstrated superior
TNF-𝛼 adsorption, which was reduced after incorporation of
PTFE.This indicated the benefit of GNP’s large, outer surface
area and underscored the importance of accessible surface
just as much as the internal porosity of ACs. Overall, the
incorporation of GNP in the PTFE film largely preserved
the GNP surface for the adsorption of mid-range molecular
weight cytokine markers IL-6 and IL-8 and demonstrated
significantly lower removal capacity of plasma TNF-𝛼 as
compared to unbound GNP. Future experiments may further
improve GNP surface area exposure by preparing VA-GNP-
PTFE film with reduced thickness and thus improve TNF-
𝛼 adsorption. This development could yield significant cost
benefits to optimize and use GNP for sepsis in blood
detoxification devices.
Novel materials developed for direct blood contacting
applications often raise hemocompatibility concerns such
as fine particle release and blood cell activation. Several of
our previously published studies have demonstrated the safe
use of carbon-based materials for direct blood contacting
applications [34, 36, 37]. Our efforts have developed a
commercially viable composite material that utilized PTFE
not only to produce a flexible freestanding film structure,
but also to hold the GNP particles in place, eliminating
fine particle release. In addition to the noncytotoxic nature
of the GNP established in this study, further research that
delves into the assessments of material hemocompatibility
will be beneficial. In particular, future efforts must ensure
that the use of this cost-effective adsorbent does not trigger
complement cascade, excessive platelet adhesion/activation,
or granulocyte activation in ex vivo setups. The GNP-PTFE
adsorbent could also be used in the plasma circuit of systems
6 Journal of Nanomaterials
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Figure 4: (a)The removal efficiency of inflammatory cytokine markers in spiked human plasma samples; GNP cytotoxicity assessments after
24 hours of direct contact using (b) MTS and (c) LDH assays. ∗ represents 𝑝 < 0.05; ∗∗ represents 𝑝 < 0.01; ∗ ∗ ∗ represents 𝑝 < 0.001;
∗ ∗ ∗∗ represents 𝑝 < 0.0001 estimated using two-way ANOVA statistic test (±standard error of mean, 𝑛 = 3).
such as MARS [38] or Prometheus [39] where adsorbent
materials do not come into direct contact with patient blood
and, therefore, mitigate issues of blood cell activation and
hemocompatibility.
4. Conclusions
In summary, we have demonstrated the use of GNP as a
fast and very efficient adsorbent with low cytotoxicity for
rapid removal of proinflammatory cytokines including IL-
8, IL-1𝛽, IL-6, IL-10, and TNF-𝛼 from human plasma on
a clinically relevant scale. The material reported in this
study shows faster adsorption compared to all other carbons
reported so far, combined with a very high sorption capacity.
Furthermore, we also developed a flexible freestanding GNP-
PTFE composite material with high accessible surface area
for targeted adsorption of cytokines and showed its potential
as hemoperfusion adsorbent. Further development of these
graphene-based sorbents should aim to confirm their ex
vivo hemocompatibility. Subsequently, future research efforts
will enhance accessible surface area for improved adsorption
of the high molecular weight cytokines including TNF-
𝛼 and bring forth a cost-effective materials solution for
hemoperfusion systems for treatment of sepsis.
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